Asuragen

Asuragen test kits to detect major and minor BCR-ABL fusions can now run on the Roche Diagnostics Cobas z 480 Analyzer.

Under the collaboration, Asuragen will develop diagnostic kits for analyzing repeat sequences using Thermo Fisher's 3500 Dx Series Genetic Analyzer CS2 instrument.

The firm, which makes both neurogenetic and oncology diagnostics, also provided updates on its market strategies and menu outlook.

The molecular test is now the first FDA-cleared assay to monitor treatment response and disease clearance in chronic myeloid leukemia patients.

When molecular testing did affect the surgical plan, it often led to overtreatment, according to the Johns Hopkins University School of Medicine team.

Asuragen will leverage its Quantidex NGS product platform and Illumina's FDA-cleared MiSeqDx instrument to develop companion diagnostics.

The assay improves upon other tests by attaining a sensitivity of MR4.7 while it allows direct reporting on the IS, Asuragen said.

Caprion, Asuragen, and the AIT Austrian Institute of Technology join the consortium launched in 2013 to develop blood-based tests for the early detection of cancers.

A study comparing DNA extracted from standardized blocks of FFPE showed variability among experienced molecular pathology labs.

NEW YORK (GenomeWeb) — Scientists from Asuragen and the New York Institute for Basic Research in Development Disabilities have published research that they claim provides the most compelling evidence to date for a relationship between AGG sequence interruptions and the risk of triplet repeat expa

Pages

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.